Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2020

View Archived Issues

Immunocytokines jumpstart anti-glioblastoma immunity

Structural insights into small-molecule GLP-1 agonists

FDA clears IND for phase I/IIa study of AstroStem-V to treat COVID-19 patients with pneumonia

Enrollment begins in phase II ASUNCTIS study of asunercept in patients with COVID-19

NIH launches ACTIV-5/BET trial to identify new promising COVID-19 treatments

New osteoporosis treatment target, inhibitor identified

Universita degli Studi di Milano and collaborators describe inhibitors of miR-129

Cyclerion provides updates on their development of olinciguat and IW-6463

New MAP3K5 inhibitors identified at Enanta Pharmaceuticals

California Institute of Technology, 1200 Pharma and UC Oakland disclose PRMT5 inhibitors

Columbia University, Forkhead BioTherapeutics synthesize new FOXO1 inhibitors

New galectin-3 inhibitors discovered at Bristol Myers Squibb

Novan presents positive in vitro data for its NITRICIL platform technology against SARS-CoV-2

FDA grants approval for expanded use of Wakix for cataplexy in adult patients with narcolepsy

Sorrento cleared for phase II trial in Brazil of abivertinib for mild, moderate and severe COVID-19

Arvinas announces new preclinical programs

Janssen begins phase III evaluation of seltorexant as adjunctive therapy for MDD with insomnia

Astellas describes discovery of novel PET probe for fatty acid oxidation

First subject dosed in phase I study of AZP-3601

FDA clears IND for 177Lu-omburtamab-DTPA

KKC-080106 shows promising neuroprotective activity in preclinical models

Ankasa begins phase Ib/IIa evaluation of ART352-L in posterolateral spinal fusion

Roche begins phase III study of GDC-9545 with palbociclib in advanced breast cancer

FDA approves Inmazeb for Zaire ebolavirus

Vertex discontinues development of VX-814 for alpha-1 antitrypsin deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...